Creating Value For Our Shareholders

Why Invest in Bayer

Report Highlights

Q1_2022_100x80

Quarterly Statement First Quarter 2022

Investment Case

Event Highlights

Girl using a drone with the sunset in the background

August 11, 2022

Crop Science Field Technology Showcase

enhancing-transparency

Enhancing Transparency: Bayer’s UN Global Compact adherence Webinar

Investor Conference Call

Q1 2022 Results

Werner Baumann & Norbert Winkeljohann

Virtual Event: Annual Stockholders’ Meeting 2022

womans face with data sheets

Bayer Breakthrough Innovation Forum

Investor Conference Call

FY/Q4 2021 Results

February 18, 2022

Nubeqa Investor Webinar February 2022

woman with plants

February 16, 2022

Crop Science R&D Pipeline Update Webinar February 2022

VIEW ALL EVENTS

News from Bayer

June 30, 2022

Not intended for U.S. and UK Media

Kerendia™ (finerenone) approved in China for the treatment of adults with chronic kidney disease associated with type 2 diabetes

June 29, 2022

Not intended for U.S. and UK Media

Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology

June 28, 2022

Not intended for U.S. and UK Media

Bayer expands Radiology Business into AI Market with Calantic™ Digital Solutions

Sustainability & Governance

Our Commitment to Sustainability

Discover More Investor Resources

Returning Value to Shareowners

Detailed Insight into Debt & Fixed Income

Discover Our Interactive Stock Charts

CORPORATE GOVERNANCE

Managing and Supervising an Enterprise

CONTACT IR TEAM

Get In Touch With Us

Subscribe To Our Latest Investor News

USES AND SAFETY RECORD

Let’s Talk About Glyphosate

Learn About The Litigation

Glyphosate Litigation Facts